Skip to main content
Terug
HNGZY logo

Hangzhou Tigermed Consulting Co., Ltd.

Datakwaliteit: 100%
Overbought
HNGZY
OTC Healthcare Medical - Diagnostics & Research
€ 4,00
€ 0,00 (0,00%)
Marktkapitalisatie: 6,16B
Dagbereik
€ 4,00 € 4,28
52-Weeksbereik
€ 4,00 € 4,28
Volume
612
50D / 200D Gem.
€ 4,00 / € 4,00
Vorige Slotkoers
€ 4,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 15,2 0,4
P/B 0,3 2,9
ROE % 1,9 3,8
Net Margin % 6,1 3,9
Rev Growth 5Y % 19,9 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 19,93% annually over 5 years — strong growth
Earnings declined -79,99% over the past year
ROE of 1,94% is below average
Debt/Equity of 0,13 — conservative balance sheet
Generating 740,45M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 30,51%

Groei

Revenue Growth (5Y)
19,93%
Revenue (1Y)-10,58%
Earnings (1Y)-79,99%
FCF Growth (3Y)-9,74%

Kwaliteit

Return on Equity
1,94%
ROIC2,14%
Net Margin6,14%
Op. Margin10,06%

Veiligheid

Debt / Equity
0,13
Current Ratio1,72
Interest Coverage4,70

Waardering

P/E Ratio
15,21
P/B Ratio0,30
EV/EBITDA10,15
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -10,58% Revenue Growth (3Y) -3,46%
Earnings Growth (1Y) -79,99% Earnings Growth (3Y) -55,07%
Revenue Growth (5Y) 19,93% Earnings Growth (5Y) -30,63%
Profitability
Revenue (TTM) 6,60B Net Income (TTM) 405,14M
ROE 1,94% ROA 1,41%
Gross Margin 33,95% Operating Margin 10,06%
Net Margin 6,14% Free Cash Flow (TTM) 740,45M
ROIC 2,14% FCF Growth (3Y) -9,74%
Safety
Debt / Equity 0,13 Current Ratio 1,72
Interest Coverage 4,70 Dividend Yield 0,03%
Valuation
P/E Ratio 15,21 P/B Ratio 0,30
P/S Ratio 0,93 PEG Ratio -0,78
EV/EBITDA 10,15 Dividend Yield 0,03%
Market Cap 6,16B Enterprise Value 6,74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 6,60B 7,38B 7,09B 5,21B 3,19B
Net Income 405,14M 2,02B 2,01B 2,87B 1,75B
EPS (Diluted) 0,47 2,34 2,32 3,30 2,19
Gross Profit 2,24B 2,85B 2,81B 2,27B 1,51B
Operating Income 664,42M 2,49B 2,58B 1,92B 1,12B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 28,67B 29,68B 27,45B 23,74B 19,51B
Total Liabilities 4,61B 5,23B 4,77B 3,14B 1,65B
Shareholders' Equity 20,67B 21,03B 19,58B 18,12B 16,12B
Total Debt 2,63B 2,83B 2,80B 1,19B 384,94M
Cash & Equivalents 2,06B 7,42B 7,86B 8,54B 10,12B
Current Assets 6,30B 11,34B 11,11B 10,85B 11,65B
Current Liabilities 3,66B 4,14B 3,73B 2,41B 1,14B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#401 of 820
42

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026